RxDoctor Payments Data

James Neff, MD

Internal Medicine · Corpus Christi, TXNPI 1013992015

Payments from drug & device makers

$994in general payments, 2019–2025

Across 86 payments — averaging $11.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$185
  • Johnson & Johnson$171
  • Astellas Pharma US Inc$115
  • Merck$85
  • Novo Nordisk$62
  • AstraZeneca$54
  • plus $321 from 11 others

What the payments were for

  • Food & beverage$89490%
  • Education$10010%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$994 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$203,815
Medicare patients
491
Services billed
9,538

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide186$234,106
JardianceEmpagliflozin102$120,866
EliquisApixaban116$105,294
XareltoRivaroxaban79$72,484
FarxigaDapagliflozin Propanediol65$71,109
TrulicityDulaglutide46$54,890
MultaqDronedarone Hcl31$34,665
ProliaDenosumab18$30,240
Repatha SureclickEvolocumab31$20,263
JanuviaSitagliptin Phosphate13$17,987
MounjaroTirzepatide15$15,787
MyrbetriqMirabegron22$15,607
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$10,250
Atorvastatin Calcium954$8,568
Rosuvastatin Calcium560$7,718

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$62$234,106186 claims
PfizerEliquis$185$105,294116 claims
Johnson & JohnsonXarelto, Invokana$171$79,88392 claims
AstraZenecaFarxiga, Symbicort$54$75,42283 claims
Lilly USA, LLCTrulicity, Mounjaro$53$70,67761 claims
Sanofi-aventis U.S. LLCMultaq$16$34,66531 claims
MerckJanuvia$85$17,98713 claims
Astellas Pharma US IncMyrbetriq$115$15,60722 claims
GSKTrelegy Ellipta$31$10,25018 claims
AbbVieSynthroid$27$4,52359 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Corpus Christi

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →